Quality Standard:【产品介绍】Alpha-Synuclein is expressed predominantly
in brain, where it is concentrated in presynaptic
nerve terminals (1). The deposition of the
abundant presynaptic brain protein alpha-synuclein
as fibrillary aggregates in neurons or glial cells is
a hallmark lesion in a subset of neurodegenerative disorders. These disorders include Parkinson's
disease (PD), dementia with Lewy bodies (DLB) and
multiple system atrophy, collectively referred to as synucleinopathies. Phosphorylation of alpha-synuclein at
Ser 129 promoted fibril formation in vitro and these
results highlight the importance of phosphorylation
of filamentous proteins in the pathogenesis of neurodegenerative disorders (2). Parkinson's disease (PD)
is a common neurodegenerative disorder characterized by
the progressive accumulation in selected neurons of
protein inclusions containing alpha-synuclein and
ubiquitin. It is hypothesized that parkin and
alpha-synculein interact functionally, namely, that
parkin ubiquitinates alpha-synuclein normally and that
this process is altered in autosomal recessive PD (3).
Recommended Applications
WB, ICC
Applications and Recommended Dilution Factors
WB: 1:1,000 - 10,000
ICC: 1:100 - 250
Species Reactivity *
Human
*Species cross-reactivity is based on WB analysis.
Products Data
Western blot analysis on HeLa cell lysates
using anti-Phospho-Alpha-Synuclein (pY125)
RabMAb (cat. #3932-1). Cells were either (A)
untreated (B) treated with pervanadate.
Specificity
A phospho specific peptide corresponding to
residues surrounding tyrosine 125 of human
Alpha-Synuclein was used as an immunogen. This antibody
only detects Alpha-Synuclein phosphorylated at tyrosine 125.